rosiglitazone has been researched along with 4-oxothiazolidine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaminskyy, D; Khyluk, D; Kryshchyshyn-Dylevych, A; Lesyk, R; Skóra, B; Szychowski, KA | 1 |
| Bar, M; Holota, S; Khyluk, D; Lesyk, R; Roman, O; Skóra, B; Szychowski, KA; Tabęcka-Łonczyńska, A | 1 |
2 other study(ies) available for rosiglitazone and 4-oxothiazolidine
| Article | Year |
|---|---|
4-thiazolidinone-based derivatives rosiglitazone and pioglitazone affect the expression of antioxidant enzymes in different human cell lines.
Topics: A549 Cells; Antioxidants; Apoptosis; Caco-2 Cells; Caspase 3; Cell Line; Cell Line, Tumor; Humans; Neoplasms; Oxidative Stress; Pioglitazone; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Thiazolidines | 2021 |
New 4-thiazolidinone-based molecules Les-2769 and Les-3266 as possible PPARγ modulators.
Topics: Antineoplastic Agents; Humans; Molecular Docking Simulation; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiazolidines | 2022 |